{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T06:02:52Z","timestamp":1740895372123,"version":"3.38.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.mayocpiqo.2023.07.001","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T10:29:12Z","timestamp":1694773752000},"page":"430-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States"],"prefix":"10.1016","volume":"7","author":[{"given":"Rafael","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric E.","family":"Chinaeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niodita","family":"Gupta-Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Z.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuchita","family":"Kaila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.07.001_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.07.001_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2023.07.001_bib4","article-title":"Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"49","author":"Wang","year":"2021","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.mayocpiqo.2023.07.001_bib5","unstructured":"DARZALEX\u00ae (daratumumab) injection [package insert]. Janssen Biotech, Inc; January\u00a02023."},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.07.001_bib6","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1186\/s12885-021-08881-7","article-title":"Treatment patterns and effectiveness of patients with multiple myeloma initiating daratumumab across different lines of therapy: a real-world chart review study","volume":"21","author":"Atrash","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2023.07.001_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/fon-2021-1072","article-title":"Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting","volume":"18","author":"Gordan","year":"2022","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.07.001_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12885-022-09980-9","article-title":"Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received bortezomib in combination with lenalidomide and dexamethasone as first line of therapy in the United States","volume":"22","author":"Medhekar","year":"2022","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2023.07.001_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.clml.2019.06.007","article-title":"Treatment patterns and clinical and economic outcomes in patients with newly diagnosed multiple myeloma treated with lenalidomide- and\/or bortezomib-containing regimens without stem cell transplant in a real-world setting","volume":"19","author":"Chari","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2023.07.001_bib10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s12325-020-01546-0","article-title":"Treatment pattern and outcomes in newly diagnosed multiple myeloma patients who did not receive autologous stem cell transplantation: a real-world observational study: treatment pattern and outcomes in patients with multiple myeloma","volume":"38","author":"He","year":"2021","journal-title":"Adv Ther"},{"issue":"22","key":"10.1016\/j.mayocpiqo.2023.07.001_bib15","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.07.001_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2023.07.001_bib17","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2023.07.001_bib18","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2023.07.001_bib19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2023.07.001_bib20","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2023.07.001_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.mayocpiqo.2023.07.001_bib22","unstructured":"DARZALEX FASPRO\u2122 (daratumumab and hyaluronidase-fihj) [package insert]. Horsham, PA: Janssen Biotech, Inc; November 2022."},{"issue":"4","key":"10.1016\/j.mayocpiqo.2023.07.001_bib23","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1200\/OP.22.00421","article-title":"Clinical administration characteristics of subcutaneous and intravenous administration of daratumumab in patients with multiple myeloma at Mayo Clinic infusion centers","volume":"19","author":"Soefje","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.07.001_bib24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00432-020-03365-w","article-title":"Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results","volume":"147","author":"Usmani","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2023.07.001_bib25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-021-00548-7","article-title":"The effect of duration of lenalidomide maintenance and outcomes of different salvage regimens in patients with multiple myeloma (MM)","volume":"11","author":"Ho","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2023.07.001_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2017.12.012","article-title":"Prolonged duration of therapy is associated with improved survival in patients treated for relapsed\/refractory multiple myeloma in routine clinical care in the United States","volume":"18","author":"Hari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"30","key":"10.1016\/j.mayocpiqo.2023.07.001_bib27","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.mayocpiqo.2023.07.001_bib28","unstructured":"RED BOOK\u00ae Online. Micromedex Healthcare Series [database online]. Greenwood Village, CO: Truven Health Analytics; 2023. Accessed January 20, 2023 (data on file)."}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454823000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454823000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:01:15Z","timestamp":1740873675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454823000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2542454823000401"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2023.07.001","relation":{},"ISSN":["2542-4548"],"issn-type":[{"type":"print","value":"2542-4548"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2023.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}